Oncolytics Biotech(R) Demonstrates Positive Data in Two Posters at AACR Annual Meeting 2018

CALGARY, AB and SAN DIEGO, CA--(Marketwired - April 18, 2018) -

- Preclinical models proved pelareorep increased PD-L1 expression in microsatellite stable (MSS) colorectal cancer cells (CRC) -

- Demonstrated efficacy of pelareorep and anti-PD1 agent combination -

Oncolytics Biotech^® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN^® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced two posters highlighting data from pelareorep studies presented at the American Association for Cancer Research (AACR) Annual Meeting 2018. The conference takes place April 14-18, 2018, in Chicago.

"These posters add additional confirmation of pelareorep's promotion of an inflammatory signature in different cell lines," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. "The study by doctor Wilkinson demonstrates that pelareorep can establish an inflamed tumor phenotype and the presentation by doctor Goel highlights the synergistic combination of pelareorep and an anti-PD1 agent. Taken together, these findings highlight that pelareorep is priming the immune system and enhancing the activity of checkpoint blockade. As MSS CRC typically does not respond to checkpoint blockade, viral priming could expand the use of this drug class by making non-susceptible tissue susceptible by turning cold tumors hot. This work will of course lead to additional studies in combination with other immunotherapies."

Presenter:	Sanjay Goel, MD, Associate Professor of Medicine, Montefiore Medical Center
Presentation Title:	Potentiating effect of reovirus in anti-PD1 therapy in colorectal cancer
Session Title:	Receptor Targeting and the Tumor Microenvironment
Location:	Poster Section 38
Poster Board #:	17
Poster Number:	3917

Data presented in the poster demonstrated: